ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
Provided By GlobeNewswire
Last update: Jul 29, 2025
Presentation to highlight the Company’s proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310
Posters highlighting PRECISE-AD, the Company’s Phase 1b clinical trial design and optimization of biomarkers in AD
Read more at globenewswire.comNASDAQ:PMN (11/5/2025, 10:41:29 AM)
0.4129
+0.01 (+1.6%)
Find more stocks in the Stock Screener
